TBH Global Asset Management LLC Has $2.73 Million Stake in Johnson & Johnson (NYSE:JNJ)

TBH Global Asset Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,921 shares of the company’s stock after acquiring an additional 142 shares during the quarter. TBH Global Asset Management LLC’s holdings in Johnson & Johnson were worth $2,729,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of JNJ. AMF Tjanstepension AB raised its stake in Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC acquired a new position in Johnson & Johnson during the third quarter worth about $209,000. Wealth Group Ltd. acquired a new position in Johnson & Johnson during the third quarter worth about $213,000. Swedbank AB grew its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Finally, Impact Partnership Wealth LLC grew its holdings in shares of Johnson & Johnson by 1.8% during the third quarter. Impact Partnership Wealth LLC now owns 7,160 shares of the company’s stock worth $1,160,000 after purchasing an additional 126 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $162.35 on Friday. The stock has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The stock’s 50 day moving average price is $148.93 and its two-hundred day moving average price is $155.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.29 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Raymond James reduced their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday. Finally, Barclays boosted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.